Lipid Disorders in Pregnancy

Author(s): Anastasios Liberis*, Stamatis Petousis, Panagiotis Tsikouras

Journal Name: Current Pharmaceutical Design

Volume 27 , Issue 36 , 2021


Become EABM
Become Reviewer
Call for Editor

Abstract:

Dyslipidemia represents a major risk factor for cardiovascular disease. In addition, severe hypertriglyceridemia is an important cause of acute pancreatitis. Accordingly, the increase in serum lipid levels that is observed during pregnancy has potentially important implications. The management of dyslipidemia in pregnancy is further complicated by the lack of safety data during this period for most of the lipid-lowering agents. In the present review, we discuss the most important lipid disorders in pregnant women and their management. Pregnancy is characterized by increases in both low-density lipoprotein cholesterol (LDL-C) and triglyceride levels, which might result in severe complications both for the mother and the fetus. Accordingly, LDL-C and triglyceride levels should be monitored during pregnancy, particularly in women with a history of dyslipidemia. Diet is the mainstay of management of dyslipidemia in pregnant women and apheresis can also be considered in patients with homozygous familial hypercholesterolemia or severe hypertriglyceridemia. However, there is a pressing need for studies that evaluate the safety of lipid-lowering agents during pregnancy.

Keywords: Dyslipidemia, pregnancy, statins, fibrates, hypercholesterolemia, hypertriglyceridemia, familial hypercholesterolemia.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 27
ISSUE: 36
Year: 2021
Published on: 20 April, 2021
Page: [3804 - 3807]
Pages: 4
DOI: 10.2174/1381612827666210421103245
Price: $65

Article Metrics

PDF: 145